Caledonia Investments said it was selling its interest in portfolio company Agilytix to Cinven for $183m.
The company said proceeds will be held for future investment. Caledonia’s shareholding in BioAgilytix was valued by Caledonia at £51m as at September 30.
The deal is subject to US anti-trust approvals and is expected to complete in December 2021.
Caledonia co-invested in BioAgilytix in February 2019 with Belgium-based investment company Cobepa and UK based specialist healthcare fund GHO Capital.
